8-K: CytoSorbents Reports Q3 2025 Results, Boosts Liquidity

CytoSorbents Corporation announced third quarter 2025 financial results, reporting 10% revenue growth, an amended credit agreement, and a workforce reduction plan aimed at achieving cash-flow breakeven by Q1 2026.

Summary

• Third quarter 2025 revenue was $9.5 million, representing a 10% increase year-over-year, or 4% on a constant currency basis, compared to $8.6 million in Q3 2024.
• Gross margin in Q3 2025 improved to 70% from 61% in Q3 2024.
• Operating loss improved to $2.9 million, compared to $4.8 million in Q3 2024.
• Net loss was $3.2 million, or $0.05 per share, compared to a net loss of $2.8 million, or $0.05 per share, in Q3 2024.
• Adjusted net loss improved to $2.6 million, or $0.04 per share, compared to an adjusted net loss of $4.5 million, or $0.08 per share, in Q3 2024.
• Adjusted EBITDA loss improved to $2.0 million compared to a loss of $3.6 million in Q3 2024.
• Total cash, cash equivalents, and restricted cash were $9.1 million on September 30, 2025, reflecting a net operating cash burn of $2.6 million in the quarter.
• Proforma cash, cash equivalents, and restricted cash was $11.6 million on September 30, 2025, assuming the additional $2.5 million term loan capital from the amended credit agreement was drawn.
• An amended credit agreement with Avenue Capital Group provides an additional $2.5 million in term loan capital and extends the interest-only period through December 31, 2026.
• An additional $2.5 million is available and the interest-only period can be further extended to June 30, 2027, upon DrugSorb-ATR FDA marketing approval.
• A Workforce and Cost Reduction Program was implemented, reducing the workforce by approximately 10%, with an expected charge of up to $900,000, aiming to accelerate cash-flow breakeven to Q1 2026.
• A De Novo pre-submission package for DrugSorb-ATR was submitted to the FDA, with a meeting expected in late Q4 2025 or early Q1 2026, followed by a planned new De Novo application submission in Q1 2026 and an anticipated regulatory decision by mid-2026.

Sentiment

Score: 7

Explanation: While the company reported an increased net loss and a regulatory setback for DrugSorb-ATR, the significant improvements in revenue growth, gross margin, and adjusted operating metrics, coupled with proactive cost reduction measures and secured additional financing, indicate a strong operational trajectory and decisive management actions. The positive clinical data further supports product efficacy, contributing to an overall positive outlook despite ongoing challenges.

Positives

• Revenue increased by 10% year-over-year to $9.5 million in Q3 2025, driven by record performance in distributor territories and strong direct sales outside Germany.
• Gross margin significantly improved to 70% in Q3 2025 from 61% in Q3 2024, due to resolved manufacturing issues and rebalanced inventory.
• Operating loss improved to $2.9 million in Q3 2025 from $4.8 million in Q3 2024, reflecting improved gross margins and lower operating expenses.
• Adjusted net loss improved to $2.6 million ($0.04 per share) in Q3 2025 from $4.5 million ($0.08 per share) in Q3 2024.
• Adjusted EBITDA loss improved to $2.0 million in Q3 2025 from $3.6 million in Q3 2024.
• The amended credit agreement provides immediate additional funding of $2.5 million and extends the interest-only period, strengthening the balance sheet and providing liquidity.
• The implementation of a Workforce and Cost Reduction Program is expected to accelerate the path to operating cash flow break-even to Q1 2026.
• Recent clinical data publications and presentations reinforce the positive clinical impacts of therapies, including significant reductions in both in-hospital and 28-30-day mortality for septic shock patients (Steindl, et al. 2025).
• DrugSorb-ATR demonstrated significant reduction of direct oral anticoagulants (DOACs) in urgent cardiothoracic surgery, supporting its potential as a broad countermeasure for blood thinners.
• Real-world data showed that combining dual antiplatelet therapy (aspirin + ticagrelor) with intraoperative CytoSorb use reduced severe bleeding complications in heart attack patients undergoing urgent CABG.

Negatives

• Net loss increased to $3.2 million in Q3 2025 from $2.8 million in Q3 2024.
• Total cash, cash equivalents, and restricted cash decreased to $9.1 million on September 30, 2025, from $11.7 million on June 30, 2025, reflecting a net operating cash burn of $2.6 million in the quarter.
• Sales in the direct German market declined, necessitating a proactive reorganization of the commercial team and selling approach.
• The company reduced its workforce by approximately 10% as part of its cost reduction plan, indicating operational adjustments.
• A charge of up to $900,000 is expected to be recorded related to severance and other restructuring costs.
• The original De Novo application for DrugSorb-ATR was denied by the FDA, requiring a new submission and extending the regulatory timeline.
• Additional warrants were issued to Avenue Capital Group to purchase 1,428,571 shares of common stock at an exercise price of $0.70, representing potential future dilution.

Risks

• The ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval for DrugSorb-ATR remains uncertain, despite the planned new De Novo submission.
• The company's ability to successfully complete its strategic workforce and cost reduction plan and achieve operating cash-flow break-even in Q1 2026 is subject to various assumptions, and actual amounts may differ materially.
• The company's ability to appropriately finance its operations and strategic initiatives is crucial, and future capital needs may arise.
• The reorganization of the direct sales team and strategy in Germany may not lead to the anticipated improved performance and execution in 2026.
• The estimated costs for the restructuring program (up to $900,000) are subject to a number of assumptions, and actual amounts may differ materially.

Future Outlook

The company expects to reach operating cash flow break-even in the first quarter of 2026, driven by its strategic Workforce and Cost Reduction Program. A formal meeting with the FDA regarding the DrugSorb-ATR De Novo pre-submission package is anticipated in late Q4 2025 or early Q1 2026, followed by the formal De Novo submission in Q1 2026, with a regulatory decision expected by mid-2026. Management also anticipates improved performance and execution in the German market in 2026 following ongoing reorganization efforts.

Management Comments

• "We are pleased with our third quarter results led by record sales in our distributor territories, strong sales in our other direct markets, and improved operating margins and cash efficiencies across the company." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.
• "This strong sales growth was partially offset by a decline in our direct German market where we continue our proactive reorganization of our commercial team and selling approach which we believe will lead to improved performance and execution in 2026." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.
• "We are pleased with the progress we are making on key strategic initiatives including strong sales in our existing core business, gross margins of over 70%, progress toward DrugSorb-ATR approval and launch in the US, and the expectation to bring the Company to cash flow breakeven in the first quarter." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.
• "This progress is further supported by the amendment of our credit agreement which we believe provides sufficient liquidity and flexibility to continue supporting our strategic growth initiatives. We appreciate the partnership with our lender – Avenue Capital Group – and look forward to continuing to execute our strategy." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.
• "We are happy to restructure the existing loan facility and provide more capital to CytoSorbents. We have been very impressed with their OUS revenue growth and how they have been impacting patients lives and want to be strong capital partners." Chad Norman, Sr. Portfolio Manager, Avenue Capital Group.
• "With a rapidly expanding foundation of clinical evidence that now encompasses hundreds of peer-reviewed publications, real-world data, and compelling success stories, CytoSorbents broad-spectrum blood purification technology continues to advance as a powerful tool for removing harmful substances and redefine how some of the most complex and life-threatening conditions are treated." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.
• "Looking ahead, we remain committed to expanding our clinical programs across all applications to further improve outcomes for patients, and to support the healthcare workers around the world who care for them." Dr. Phillip Chan, Chief Executive Officer of CytoSorbents.

Industry Context

CytoSorbents operates in the specialized and critical field of blood purification for life-threatening conditions in intensive care and cardiac surgery. The company's focus on expanding its clinical evidence base and pursuing regulatory approvals for devices like DrugSorb-ATR aligns with the broader medical device industry's trend towards evidence-based medicine and addressing unmet needs in acute care. The emphasis on real-world data for regulatory submissions reflects an evolving landscape where clinical effectiveness in diverse settings is increasingly valued by regulatory bodies.

Comparison to Industry Standards

• CytoSorb is approved in the European Union and distributed in over 70 countries, with nearly 300,000 devices used cumulatively, indicating significant global adoption and market penetration for a specialized medical device.
• The retrospective study of 175 septic shock patients (Berlot, et al. 2025) and the first meta-analysis of 744 patients (Steindl, et al. 2025) from Charit Berlin Hospital demonstrated significant reductions in both in-hospital and 28-30-day mortality with CytoSorb usage in septic shock, suggesting a strong clinical performance compared to standard care.
• Prof. Richard Whitlock's presentation on DrugSorb-ATR's ability to significantly reduce levels of direct oral anticoagulants (DOACs) such as Eliquis (apixaban, Pfizer/Bristol Myers Squibb) and Xarelto (rivaroxaban, Janssen/Bayer) in urgent cardiothoracic surgery positions it as a potentially superior 'one-size fits all countermeasure' for blood thinners, addressing a critical need in cardiac surgery where rapid reversal is often required.
• Professor Matthias Thielmann's real-world data demonstrated that combining dual antiplatelet therapy (aspirin + ticagrelor) with intraoperative CytoSorb use reduced severe bleeding complications in heart attack patients undergoing urgent CABG, compared to patients treated with aspirin + Plavix (clopidogrel) without CytoSorb, suggesting an improved treatment protocol for managing perioperative bleeding risks.

Stakeholder Impact

• Shareholders: Potential for future dilution from warrants issued to Avenue Capital Group. The improved operational performance and strategic initiatives could positively impact long-term share value, but the increased net loss and FDA delay introduce short-term uncertainty.
• Employees: Approximately 10% of the workforce was reduced as part of the cost reduction program, directly impacting affected employees.
• Customers: Continued availability of CytoSorb and ongoing clinical evidence reinforce the benefits of the company's therapies. The pursuit of DrugSorb-ATR approval offers potential new treatment options in the U.S. and Canada.
• Creditors (Avenue Capital Group): The amended credit agreement provides additional capital and extends the interest-only period, while also granting warrants, reflecting a continued partnership and investment in the company's future.

Next Steps

• Continue proactive reorganization of the commercial team and selling approach in Germany to improve performance and execution in 2026.
• Hold a formal meeting with the FDA in late Q4 2025 or early Q1 2026 to confirm requirements for the new DrugSorb-ATR De Novo application.
• Submit the new De Novo application for DrugSorb-ATR to the FDA in Q1 2026.
• Await the anticipated regulatory decision for DrugSorb-ATR by mid-2026.
• Expand clinical programs across all applications to further improve outcomes for patients.
• Host a live conference call, presentation webcast, and question-and-answer session on November 13, 2025, at 4:30 PM ET to discuss the financial results and business update.
• Pursue regulatory approval for DrugSorb-ATR with Health Canada with better visibility from the FDA.

Key Dates

Recommendation

While CytoSorbents demonstrated strong operational improvements in Q3 2025, including 10% revenue growth and a significant increase in gross margin, the company continues to operate at a net loss and experienced cash burn. The strategic workforce reduction and amended credit agreement are positive steps towards achieving cash-flow breakeven by Q1 2026, providing necessary liquidity. However, the delay in DrugSorb-ATR's FDA approval, requiring a new De Novo submission, introduces continued regulatory uncertainty and pushes back potential market entry. The issuance of warrants to Avenue Capital Group also represents potential future dilution. The stock is a "hold" as the positive operational momentum and strategic actions are balanced by ongoing losses, cash burn, and regulatory hurdles for a key product. Investors should monitor the progress towards cash-flow breakeven and the DrugSorb-ATR FDA approval process.

Keywords

CytoSorbents, CTSO, blood purification, sepsis, septic shock, DrugSorb-ATR, FDA approval, medical device, critical care, cardiac surgery, financial results, Q3 2025, workforce reduction, credit agreement, gross margin, operating loss, EBITDA